|Addictions|| Current Smoker
| ||Supplementation with a rose-hip drink containing Lactobacillus plantarum 299v (500,000,000 colony-forming units/mL; 400 mL/d) reduced blood pressure and improved markers of cardiovascular disease risk in a study of 36 heavy smoking adults. [Am J Clin Nutr 2002;76(6): pp.1249-55]|
| ||Supplementation with one pound (1/2kg) of yogurt, but not partially skimmed milk at the same dose, improved symptom scores and immune markers of allergic reactivity in a study of 13 people with allergic rhinopathy. [Eur J Clin Nutr 2002;56(12): pp.1155-61]|
Allergic Rhinitis / Hay Fever
| ||Supplementation with one pound (1/2kg) of yogurt, but not partially skimmed milk at the same dose, improved symptom scores and immune markers of allergic reactivity in a study of 13 people with allergic rhinopathy. [Eur J Clin Nutr 2002;56(12): pp.1155-61]|
Allergy to Cow's Milk
| ||Oral administration of probiotic bacteria has been shown to stabilize intestinal integrity, promote local IgA production and reduce intestinal inflammation in atopic individuals with cow’s-milk allergy.|
| ||Use of a good probiotic product can help keep the bacterial flora in balance and reduce inflammation. Caution is advised with active inflammation, as bacteria may penetrate the gut wall and enter the blood stream.|
| ||Dr. McCann, originally with Kaiser Permanente in Ohio, has pioneered a dramatic, experimental treatment for inflammatory bowel disease which has induced a rapid remission in 16 out of 20 patients with ulcerative colitis. A two-day course of multiple broad-spectrum antibiotics to "decontaminate" the gut is followed by administration of defined strains of E. coli, and Lactobacillus acidophilus to produce a "reflorastation" of the colon. Others have not achieved this same degree of success.|
In another clinical trial, 77% of those treated with a probiotic bacteria mixture experienced relief of their mild to moderate ulcerative colitis. Of the 34 patients treated, 26 demonstrated improvement in their condition, with most of those experiencing a complete remission. Only three patients found their condition worsened after the treatment. [American Journal of Gastroenterology July 2005; 100(7):1539-46]
The mixture of eight lactic acid bacterial species is believed to work by:
Another product, available over the counter (OTC) is VSL#3. This is a high-concentration probiotic preparation of eight live freeze-dried bacterial species that are normal components of the human gastrointestinal microflora, including four strains of lactobacilli (Lactobacillus casei, L. plantarum, L. acidophilus, and L. delbrueckii subsp. Bulgaricus), three strains of bifidobacteria (Bifidobacterium longum, B. breve, and B. infantis), and Streptococcus salivarius subsp. Thermophilus. Data from noncomparative trials suggest that VSL#3 has clinical potential in the treatment of active mild to moderate ulcerative colitis and as maintenance therapy for patients with ulcerative colitis in remission. In addition, a randomized, open-label, multicenter trial showed that VSL#3 in combination with low-dose balsalazide (a prodrug of mesalazine [mesalamine; 5-aminosalicylic acid]) was more effective than standard doses of basalazide or mesalazine monotherapy in the treatment of acute mild to moderate ulcerative colitis.
- Reducing the number of "bad" bacteria
- Reducing the amount of inflammation
- Increasing the mucus layer in the gut
- Increasing the amount of anti-inflammatory molecules in the intestine
In a series of mouse experiments (2007), researchers at the Harvard School of Public Health (HSPH) have pinpointed a specific immune deficiency as the likely fundamental cause of ulcerative colitis, a chronic, sometimes severe inflammatory disease of the colon or large intestine that afflicts half a million Americans. Remarkably, the researchers also found that once the disease was established in mice, it could be passed from mother to offspring and even between adult animals, with potential implications for public health and prevention.
The researchers have linked ulcerative colitis in mice to a deficiency of a molecular "peacekeeper" in the immune system, allowing harmful bacteria in the large intestine to breach the bowel's protective lining and trigger damaging inflammation.
In a paper posted online by the journal Cell, a team led by Laurie Glimcher, Irene Heinz Given Professor of Immunology at HSPH, details a series of immunological events by which a shortage of a regulatory protein called T-bet opens the way to a bacterial attack on the intestinal wall. The resulting inflammation, in turn, causes the characteristic colitis marked by open sores, or ulcerations, throughout the colon. The first co-authors of the paper are Wendy Garrett, a research fellow in the laboratory of Glimcher and a clinical fellow at Dana-Farber Cancer Institute, and Graham Lord, formerly at HSPH and now a Professor of Medicine at King's College, London.
The key abnormality is a deficiency of the T-bet protein in "dendritic" cells -- white blood cells that capture identifying antigens of foreign microbes and activate the immune defenses. T-bet, discovered in 2000 in Glimcher's laboratory, is a "master regulator gene," a transcription factor that orchestrates a pro-inflammatory response of the immune system. T-bet had been found to play a role in the body's handling of infectious microbes and cancer cells and has been implicated in rheumatoid arthritis and asthma, but the discovery of its pivotal part in the innate immune system in inflammatory bowel disease came as a total surprise.
"We have identified a new molecular player, T-bet, and when it's missing, there is spontaneous onset of the disease in the mice," said Glimcher. "The importance of this study is that we now have a novel model for ulcerative colitis: The disease appears in 100 percent of the animals and looks just like the human disease."
If some people develop ulcerative colitis because of T-bet DNA variation or polymorphisms, it may be because of an inherited variation in the DNA affecting the T-bet gene. The researchers are following up this lead.
With its close mimicry of human ulcerative colitis, the animal model will have unprecedented value for testing new therapies and preventive measures, said Glimcher, who is also a professor of medicine at Harvard Medical School.
Ulcerative colitis and a related disorder, Crohn's disease, are known collectively as inflammatory bowel disease: they affect an estimated one million people in the United States. Crohn's disease tends to involve the small intestine as well as the colon. Ulcerative colitis usually appears between ages 15 and 30 but also can begin in the 50s and 60s, especially in men. The disease is somewhat more common among men than women, whites than non-whites, and Ashkenazi Jewish individuals than non-Jewish individuals.
Since about 20 percent of patients with ulcerative colitis have a close relative with the disease or with Crohn's disease, scientists have hunted specific genes that may be involved. Studies of the pathology of the inflamed intestine have suggested that an abnormal immune reaction and injury by bacterial residents of the colon are to blame. The T-bet shortage described in the Glimcher paper links these two mechanisms.
Beneficial bacteria in the colon aid in digestion and extraction of nutrients from food. However, harmful microbes also reside in the intestine, so animals that harbor bacteria have evolved a boundary, or barrier, in the form of the intestinal lining to keep the dangerous bacteria from injuring the colon wall.
The key to maintaining this mucosal barrier, the scientists discovered, is the "peacekeeper" activity of T-bet in the dendritic cells of the intestine's immune system. When T-bet is at normal levels, the boundary - a kind of demilitarized zone - remains intact and prevents trouble from pathogenic bacteria. But if T-bet is insufficient, the dendritic cells overproduce a powerful chemical called TNF-alpha (tumor necrosis factor-alpha) that triggers inflammation and causes normal cells to die. In ulcerative colitis, the T-bet-related excess of TNF-alpha leads to the death of cells making up the epithelial barrier of the colon, enabling harmful bacteria to chronically inflame the intestinal wall.
The scientists bred strains of mice that lacked T-bet and showed that the resulting disease was virtually identical to human ulcerative colitis.
Moreover, the investigators demonstrated that female mice with the disease could transmit it to baby mice that had adequate levels of T-bet. (The scientists placed genetically normal infant mice with the sick foster mother on their day of birth.) Presumably, the flourishing colonies of colitis-causing bacteria were passed down from the sick mother to the fostered mice. The disease was even "horizontally" transmissible from T-bet-deficient adult mice with ulcerative colitis to other adults with normal T-bet, through fecal-oral and skin-to-skin contact.
Inflammatory bowel disease can be treated with antibody drugs that block TNF-alpha activity, though their toxicity limits their use. The researchers showed that such antibody drugs cured and also prevented ulcerative colitis in T-bet-deficient mice. However, they are pursuing other potential therapies, such as increasing T-bet levels in the immune cells, administering natural immunity-dampening cells called T-regulatory cells, or giving "probiotics" - healthful bacteria that can keep the harmful microbes under control.
Microscopic Colitis (Collagenous Colitis / Lymphoc
IBS (Irritable Bowel Syndrome)
| ||Whenever antibiotics are used to treat bacterial overgrowth, probiotics should be used during and/or afterwards to help restore a healthy balance of gut flora.|
Additionally, in IBS there is a deficiency of bacteria that break down starch. Encouraging the growth or addition of these bacteria is advisable. The following study demonstrates this need and improvement with a specific probiotic formula.
Irritable bowel syndrome (IBS) represents one of three major forms of chronic inflammatory bowel disease. The aim of the present study was to investigate the composition and metabolic activities of faecal flora in IBS patients that may take part in initiation and/or maintaining of the disease state. All experiments were designed for three groups of stool donors: healthy individuals, patients with irritable bowel syndrome (IBS) diagnosis before and after treatment by prebiotic preparation Hylak Tropfen Forte.
The faecal short chain fatty acid (SCFA) profile of IBS patients was characterized by lower concentration of total SCFA, acetate and propionate (88.15, 60.16 and 18.06 mmol/l, resp.) and by higher concentration of butyrate (9.93 mmol/l). After Hylak Tropfen Forte treatment, the concentration of total short chain fatty acids (SCFA), acetate and propionate increased (100.66, 75.60 and 18.21 mmol/l, resp.). On the other hand the butyrate concentration was lowered (from 9.93 to 6.84 mmol/l). SCFA concentrations in the control group samples for total SCFA, acetate and propionate were as follows: 108.95, 73.26, 26.08 mmol/l.
Patients with irritable bowel syndrome diagnosis showed significant changes in faecal bacterial population. There were increased numbers of facultative anaerobes and sulphate reducing bacteria. Significantly lower were the counts of cellulolytic bacteria. Total counts of pectinolytic, proteolytic, lactate utilizing and lipolytic bacteria were not significantly different. After treatment with Hylak Tropfen Forte the counts of facultative anaerobes and sulphate reducing bacteria decreased and proportion of cellulolytic bacteria increased significantly and were closer to numbers in faecal samples from healthy persons. This activity could be therefore a possible indicator of irritable bowel syndrome.
Fecal bacteria from all three groups of donors were tested for their ability to degrade cellulose, pectin and starch in vitro. Starch degradation was significantly depressed in IBS patients and lower concentrations of acetate, propionate and butyrate were found. Pectin degradation in vitro followed a similar pattern. No degradation of cellulose was found. After treatment with Hylak Tropfen Forte bacterial degradation of these polysaccharides increased but not to the levels of the control group. [Kopecný J., J. Šimunek: Cellulolytic Bacteria in Human Gut and Irritable Bowel Syndrome. Acta Vet. Brno 2002, 71: 421-427]
Separately, a systematic review of the efficacy of probiotics in IBS that included 19 randomized controlled trials in 1,628 IBS patients found that "probiotics are effective in IBS, but we do not have enough information to be sure whether there is one probiotic that is particularly effective or whether combinations of probiotics are required," according to Dr. Paul Moayyedi, the study's lead researcher. [Moayyedi and co-investigators at Mayo Clinic in Jacksonville, FL and Rochester, MN; McMaster University in Ontario, Canada; University College in Cork, Ireland and Montefiore Medical Center in New York City, conducted this meta-analysis presented at the ACG Annual Scientific Meeting 2008 in Orlando.]
Here is someone's testimony about their experience with symptoms, fiber, and probiotics.
I have suffered with allium intolerance since I was about 16 or 17. Like most of you I worked it out for myself - I went to my GP and got told I had "IBS" and to "just deal with it". She was very unsympathetic and gave me these fibre supplement drinks (GROSS) which made me 100 x worse. I saw another doctor when I got really bad (diahorrea and cramps every day for a month) & he referred me to a dietician who was wonderful and helped sooo much. She said taking all that fibre was probably the WORST thing I could have done!
This is what she said (in a nut shell):
Your gut is meant to contain lots of good bacteria to help with digestion.
Bacteria living on the gut wall feed off fibre.
Apparently the gas, bloating, diarrheoa etc is caused by bad bacteria in the gut. Taking pro-biotics at this stage is no good because if there is so much bad bacteria on your gut wall - there is no space for the good bacteria to live.
Increasing your fibre intake (like I did) will just make the bad bacteria thrive.
First you need to kill the bad bacteria and to do this I was put on a fibre-free diet for 2 weeks. Basically all the stuff you're usually told is unhealthy - white bread no crusts potatos - no skins. The cramps and other symtoms almost instantly subsided - it was miraculous!!
After this I had lots and lots of probiotics - yoghurts and drinks etc to increase the good bacteria in my gut and slowly reintroduced fibre.
It really worked - I couldn't believe it after trying so many other things!
Anyway, whenever my IBS symptoms get really bad (luckily not very often now) I just follow the advice she gave me. I also avoid onions, leeks, chives and shallots like the plague.
I have set up a group on facebook (just search for "onion allergy/intolerance") or click on my website. I have started compiling some recipes and a list of onion-free supermarket finds on there. I hope people will find it useful and maybe help me add to it!
This and other stories found here make for some interesting reading.
| ||A study of hospitalized children showed that a combination of Lactobacillus acidophilus and Bifidobacterium infantis was effective in treating acute diarrhea. One of the more common causes for hospitalization of infants and young children is dehydration related to acute diarrhea, especially from a rotavirus. Lactobacilli in the intestines play an important role in developing natural defenses against both intestinal bacterial and viral infections. In the study group, the frequency of diarrhea improved on the first and second day of hospitalization and the duration of diarrhea during hospitalization also decreased. The researchers concluded "Oral bacterial therapy is an effective adjuvant therapy in rotavirus positive and negative children with diarrhea and can safely be administered during an episode of acute diarrhea." [Acta Paediatr Taiwan 2001 Sep-Oct; 42(5): pp.301-5]|
Probiotics appear to be effective in treating acute diarrhea, according to researchers from Johns Hopkins Bloomberg School of Public Health. They conducted a meta-analysis of 34 masked, randomized, placebo-controlled trials. One was carried out in a developing country, while the others were carried out in health-care settings in developed countries. They found that probiotics reduced:
Further, risk of acute diarrhea among children and adults was reduced by 57% and 26%, respectively, when probiotics were used.
- Antibiotic-associated diarrhea by 52%
- Traveler's diarrhea by 8%
- Acute diarrhea of diverse causes by 34%
Several probiotic strains, including Saccharomyces boulardii, Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, and others, were evaluated. No significant difference was found between the different strains used, alone or in combination. [The Lancet Infectious Diseases June 2006, Vol. 6, No. 6: 374-382]
Dr. Mercola, of Internet fame, says "When treating acute infectious diarrhea, large therapeutic doses are required (typically an entire bottle over a day's time or about an eighth of a bottle every hour until the problem is resolved). Most often, the symptoms will subside within four hours."
Heartburn / GERD
| ||The use of acidophilus capsules has helped relieve heartburn in some patients.|
| ||In a controlled trial of one month, 56 weaning infants were supplemented with fructo-oligosaccharides in their cereal ( 0.75g FOS per serving of cereal; average FOS consumption 0.74g per day). This resulted in more regular, softer stools and less frequent symptoms of constipation. [Br J Nutr 2003;90(3): pp.581-8]|
Upcoming Surgical Procedure
| ||Probiotic use before surgery can be helpful in maintaining a healthy colonic flora if antibiotics are going to be used after your surgery. Do not use probiotics without your doctor's approval if your immune system is seriously compromised.|
Immune System Imbalance (TH2 Dominance)
| ||The specific bacteria that that help balance a TH2 dominant immune system are:|
Soil Based Organisms (SBOs) (bacillus subtilis and lichenformis) produce surfactin that inactivates lipid envelope viruses (HIV, CMV, herpes etc), kills mycoplasmas, many bacteria and candida albicans. By reducing candida albicans, SBOs reduce TH2 cytokines.
- Lactobacillus Plantarum and L casei - potent inducers of IL-12 and IFN-gamma. They support mucosal immunity.
- Bifidobacterium longum - increases IgA (supports mucosal immunity) - reduces candida albicans - improves lactose tolerance.
- Acidophilus - promotes resistance to colonization of candida albicans.
| ||One of the ways to help reestablish a balanced bacterial population in the GI tract is the use of probiotics. There are many products on the market containing a variety of organisms and a general approach could be taken using a broad spectrum probiotic formula. However, a better method is to discover the type of imbalance by testing and then supplementing those specific bacteria that are needed. Bringing these normally-occurring bacteria into balance will help prevent the overgrowth of more pathogenic organisms.|
Bifidobacteria are the predominant lactic acid bacteria of the colon with a concentration that is 1000 times higher than Lactobacilli. Administration of Bifidobacterium brevum to humans and animals reduces fecal concentrations of Clostridia and Enterobacter species, ammonia, and toxin-releasing bacterial enzymes including beta-glucuronidase and tryptophanase. Bacillus laterosporus, a novel organism classified as non-pathogenic to humans, produces unique metabolites with antibiotic, antitumor and immune modulating activity. This organism is available as a food supplement in the United States. It has been found to be an effective adjunctive treatment for control of symptoms associated with small bowel dysbiosis in a number of patients.
Fructose-containing oligosaccharides (FOS), found in vegetables like onion and asparagus, have been developed as a food supplement for raising stool levels of Bifidobacteria and lowering stool pH.
| ||If taking antibiotics for Lyme disease, remember that they will kill both good and bad microorganisms. Replacing the friendly intestinal organisms killed with antibiotics by eating live culture yogurt or taking probiotic capsules regularly for at least six months is recommended. The aim of this treatment is to recolonize the intestine both during and after antibiotic use.|
Yeast / Candida
| ||The use of probiotics to help keep candidal overgrowth from occurring is a common part of many antifungal programs. However, in a privately funded study, Lactobacillus acidophilus, when used alone as a treatment for candida overgrowth, failed to produce any benefit. L. acidophilus, along with other bacteria, should be used as part of a more comprehensive treatment approach for known or suspected candidal overgrowth.|
Other bacteria have proven to be more effective. A product called ThreeLac claims to:
For maximum benefit, an anticandidal diet is recommended also.
- Inhibit the growth of harmful bacteria that cause digestive stress
- Improve digestion of food and absorption of nutrients
- Stimulate the body’s natural defense mechanism - the immune system
- Reduce candida overgrowth
Helicobacter Pylori Infection
| ||Supplementation for one month with Lactobacillus and Bifidobacterium yogurt after one week of triple antibiotic therapy enhanced H. Pylori eradication. Only those patients supplemented with yogurt showed restoration of Bifidobacterium in their stools compared to the levels at the beginning of the trial. [Aliment Pharmacol Ther 2002;16(9): pp.1669-1676]|
Using Lactobacillus johnsonii from a fermented milk product for 4 months reduced gastric inflammation and H. pylori density and improved mucus thickness in a well-controlled study of 50 patients with gastritis and H. pylori. [Aliment Pharmacol Ther 2003;18(8): pp.805-14]
A review of thirteen human studies concluded that probiotics may have a place as prophylaxis and supportive treatment of Helicobacter pylori infections. [Int J Antimicrob Agents 2003;22(4): pp.360-6]
Cystitis, Bacterial Bladder Infection
| ||Dr. Andrew Bruce, Chief of Urology, and Dr. Gregor Reid, Director of Urology Research, at Toronto General Hospital have been studyed women with chronic bladder infections."When we looked at the two groups of women, those who did |
not have infections, had beautiful growths of lactobacilli," Dr. Bruce commented in the Toronto Star (Apr13/92). "The lactobacilli seem to have a protective effect. A significant number of women who had repeated infections had a poor population of lactobacilli."
As a result, Dr. Bruce and his research team developed an experimental vaginal suppository called Restoration Plus. It contains two key strains of lactobacilli called lactobacillus casei and lactobacillus fermentum. In the study, one group of 28
women with four proven bladder infections within the past 12 months, was treated with the acidophilus suppositories; the other group with inert suppositories. Another arm of the study treated 40 women with acute bladder infections with a three-day course of antibiotics followed by a three-month course of Restoration Plus, and compared it to results with 20 women treated with antibiotics followed by three months of placebo.The results of this study have shown Restoration Plus to be a very effective preventative treatment for bladder infections. The treatment is given once a week for six to 12 months.
This experimental product does not appear to be available to the public at this time. A similar product, Urex-Cap-5, developed by Urex Biotech Inc., seems poised for marketing but does not yet appear to be available either.
| ||Probiotics may interfere with the development of NASH at various levels:|
Evidence in experimental animal models of fatty liver disease, as well as clinical data on other gastrointestinal diseases, strongly suggest that probiotics might be beneficial in NASH. [J Hepatol 38:pp. 681-687, 2003] Data from an uncontrolled clinical trial with NASH patients show promising results, with improvement of liver enzymes in treated patients. [Am J Gastroenterol 97:pp. 2144-2146, 2002]
- Decreases in proinflammatory cytokines, such as TNF.
- Alteration of the inflammatory effects of pathogenic strains of intestinal bacteria, through changes in cytokine signaling.
- Replacement of pathogenic strains of bacteria.
- Improved epithelial barrier function, thereby avoiding excessive exposure of the liver to LPS and bacterial ethanol.
| ||The use of probiotics can be helpful in maintaining a healthy bacterial population with uncomplicated diverticulitis. Probiotics, especially Bifidus bacteria, help reduce inflammation in inflammatory bowel disease and should provide benefit in diverticular disease by reducing pathogenic bacteria presence or overgrowth.|
| ||Probiotics should be taken after a course of antibiotics. The long term use of antibiotics for prostatitis has been found to destroy the normal urethral flora that would otherwise interfere with virulent organisms.|
| ||See the link between Pancreatitis and Dysbiosis, Bacterial.|
February 18, 2008 — In patients with predicted severe acute pancreatitis, probiotic prophylaxis did not reduce the risk for infectious complications and was associated with an increased risk for mortality, according to the results of a multicenter, randomized, double-blind, placebo-controlled trial reported in the February 14 Online First issue of The Lancet.
The researchers conclude from these findings that prophylaxis with this combination of probiotic strains should not be administered in this category of patients as it did not reduce the risk of infectious complications and was associated with an increased risk of mortality.
This study does not negate the potential benefit of a specific probiotic discussed in the link mentioned at the top of this comment. The combination probiotic used in the Lancet study contained different Lactobaccilus strains and other species.
| ||If Y. enterocolitica is involved in the initiation (and continuance) of EN, then using a probiotic may help oppose this dysbiosis.|
Possible Pregnancy-Related Issues
| ||Gastrointestinal alterations in bacterial flora are common in infants suffering from allergic disease or who will develop allergic disease later. Probiotic supplementation helps normalize and strengthen the lining of the GI tract in infants. Eczema symptoms have been reduced in infants when they were supplemented with probiotics. In addition, probiotic supplementation in mothers for 6 months before and after birth reduced the incidence of eczema in their children by 50%. [Brit J Nutr 2002 Sep; 88 Supp 1: pp. S19-27] Antibiotic use in early infancy has been associated with an increased risk of allergic disease in later childhood, which is in keeping with the understanding that a disturbed GI flora will contribute to an allergic tendency. A family history of atopic disorders like dermatitis further suggests that probiotic supplementation would be wise both pre- and postnatally.|
| ||Twice-daily vaginal douches, using 2 teaspoons full of acidophilus / bifidus powder in a quart of warm water, will help treat many recurrent vaginal yeast infections. Even just taking probiotics orally will increase the colonization of these organisms in the vagina and help prevent infections from occurring. The use of 'live culture' yogurt can also reduce or eliminate vaginal yeast infections as the organisms are able to find their way to the vagina, helping to establish a more candida resistant environment.|
Several lactobacillus species given in suppository form have shown clinical efficacy as a treatment for vaginal infections. Acidophilus suppositories seem to stimulate the normal growth of lactobacilli in the vagina, reducing bacterial vaginosis and have reduced the frequency of urinary tract infections as well. If no specifically designed product is available to you, inserting a capsule of mixed acidophilus species (designed for oral use) once per day should accomplish the task of reestablishing a friendly floral environment and normalizing vaginal pH.
One study using intravaginal capsules of bacteria showed that the specific type of one bacteria over another related one may be better at recolonizing the vagina. The administration of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 promoted healthy vaginal ecology and helped prevent the development of yeast vaginitis. However, Lactobacillus GG, which has been well documented as a beneficial organism for the human digestive tract, was less able to colonize the genitourinary tract. [JAMA 2002;287: pp.1940-1941]
There is an OTC product made by Jarrow called Fem-dophilus which contains GR-1 and RC-14. It is designed to be taken orally. The oral use (taken by mouth) of these bacteria in two trials have demonstrated the ability to restore a healthy vaginal balance of bacteria. [FEMS Immunol Med Microbiol, 2003;35: pp.131-134]
| ||Gastrointestinal alterations in bacterial flora are common in infants suffering from allergic disease or who will develop allergic disease later. Probiotic supplementation helps normalize and strengthen the lining of the GI tract in infants. Eczema symptoms have been reduced in infants when they were supplemented with probiotics. In addition, probiotic supplementation in mothers for 6 months before and after birth reduced the incidence of eczema in their children by 50%. [Brit J Nutr 2002 Sep; 88 Supp 1: pp. S19-27] Antibiotic use in early infancy has been associated with an increased risk of allergic disease in later childhood, which is in keeping with the understanding that a disturbed GI flora will contribute to an allergic tendency. A family history of atopic disorders like dermatitis further suggests that probiotic supplementation would be wise both pre- and postnatally.|| |